Related Experiment Video

Updated: Dec 13, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.3K

JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients

Patricio Rojas1, Mauricio Sarmiento2

  • 1Adult Hematopoietic Stem Cell Program, Department of Hematology and Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile.

Acta Haematologica
|July 30, 2020
PubMed

Insights

Ruxolitinib, a JAK/STAT pathway inhibitor, shows promise in treating severe COVID-19. Three patients with severe coronavirus disease 2019 (COVID-19) experienced rapid and sustained recovery after treatment with this intervention.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • The global health crisis caused by COVID-19 necessitates effective treatments.
  • High contagiousness and mortality rates of COVID-19 underscore the need for novel interventions.
  • The JAK/STAT pathway is implicated in the inflammatory response to SARS-CoV-2.

Observation:

  • Three patients presented with severe manifestations of COVID-19.
  • Standard treatments did not yield sufficient improvement in these cases.
  • Ruxolitinib was administered as a potential therapeutic option.

Findings:

  • All three severe COVID-19 cases showed rapid clinical improvement following ruxolitinib administration.
  • Sustained positive outcomes were observed in the treated patients.
  • Ruxolitinib effectively modulated the aberrant immune response associated with severe COVID-19.

Implications:

  • Ruxolitinib represents a potential therapeutic strategy for severe COVID-19.
  • Targeting the JAK/STAT pathway may be beneficial in managing critical COVID-19.
  • Further clinical trials are warranted to confirm the efficacy and safety of ruxolitinib in a larger COVID-19 patient cohort.

Keywords:
COVID-19InflammationJAK/STATRuxolitinib

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.6K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.2K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
472
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
2.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
355